<DOC>
	<DOCNO>NCT02764229</DOCNO>
	<brief_summary>The purpose study allow subject complete study LYC-30937-2001 opportunity receive LYC-30937-EC 25 mg .</brief_summary>
	<brief_title>Open-label Extension Study Assess Safety Tolerability LYC-30937-EC Subjects With Active Ulcerative Colitis</brief_title>
	<detailed_description>Subjects complete 8 week treatment period double-blind , placebo-controlled study LYC-30937-2001 option receive LYC-30397-EC 25 mg PO QD open-label extension study ( LYC-30937-2002 ) . Subjects meet eligibility criterion enter open-label extension trial upon completion LYC-30937-2001 Week 8 study procedure . This open-label extension study consist 44 week treatment follow 2 week post-treatment follow-up .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Completed 8week doubleblind treatment period study LYC309372001 Male females childbearing potential must agree use adequate birth control study 30 day discontinue study drug Nonpregnant , nonlactating female plan become pregnant enrol study Investigator consider safe potentially beneficial participate Ability provide write informed consent compliant study schedule Subjects complete study LYC309372001 , experience serious adverse event consider related investigational product , unstable medical condition , reason opinion investigator participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>